LPHM News 0.0150 Lee Pharmaceuticals (LPHM)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lee Pharmaceuticals (LPHM) 0.0150 $LPHM

Investigation Report on China's Insulin Lispro Market, 2009-2018
M2 - Wed Mar 19, 9:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2w4ssh/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2009-2018" report to their offering. According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries. The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name ""Humalog"" was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion. Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market. Key Topics Covered: 1 Relevant Concepts of Insulin Lispro 2 Market Overview of Insulin Lispro in China 3 Investigation on Sales Value of Insulin Lispro in China, 2009-2013 4 Investigation on Market Share of Major Insulin Lispro Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Lispro by Dosage Form in China, 2009-2013 6 Reference Price of Insulin Lispro Produced by Different Enterprises in China Hospital Market, 2014 7 Major Manufacturing Enterprises in China Insulin Lispro Market, 2009-2013 8 Prospect of China Insulin Lispro Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/2w...estigation

Investigation Report on China's Insulin Glargine Market to 2018
M2 - Thu Mar 06, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/tgjsv7/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" report to their offering. In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition. The CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to CRI's investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention. Key Topics Covered: 1 Relevant Concepts of Insulin Glargine 2 Market Overview of Insulin Glargine in China 3 Investigation on Sales Value of Insulin Glargine in China, 2009-2013 4 Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013 6 Reference Price of Insulin Glargine in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013 8 Prospect of China Insulin Glargine Market, 2014-2018 Companies Mentioned - Aventis Behring GmbH - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tg...estigation

China Insulin Industry Report, 2012-2015
M2 - Wed Jan 23, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/48k59t/china_insulin) has announced the addition of the "China Insulin Industry Report, 2012-2015" report to their offering. Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so. Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China's insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011. Key Topics Covered: 1. Insulin Overview 1.1 Definition 1.2 Classification 1.3 Industry Chain 2. Global Insulin Market Development 2.1 Status Quo 2.2 Supply and Demand 2.3 Product R&D 2.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 44

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 48

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 36

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 37

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 15

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 76

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 90

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading

Top 5 Most Recently Viewed Articles

Infosys Partners with Meta to Lead AI Innovations Forward

Updated Category News Views 205

Infosys Enhances Partnership with Meta for AI Advancements Infosys (NSE: INFY, BSE: INFY, NYSE: INFY), a leading player in digital services and consulting, is thrilled to announce an expansion of its collaborative efforts with Meta Platforms, Inc. This partnership is aimed at pioneering new innovations in generative artificial intelligence (AI) by emphasizing open-source...

Continue Reading
Key Stocks to Monitor Midweek: Highlights from the Market

Updated Category News Views 239

Market Overview As the trading day unfolds with U.S. stock futures showing mixed signals, several companies are drawing the attention of investors. This article explores some key stocks to watch this week, highlighting their expected performance and noteworthy developments. Chewy Inc. Earnings Preview Analysts are eager to see how Chewy Inc. (NYSE: CHWY) will perform,...

Continue Reading
AI and Personalized Learning: Shaping Future Education Models

Updated Category News Views 238

AI Meets Education: A Spotlight on Everest Nevraumont In the education arena, some stories demand your attention. One such narrative is that of 11-year-old Everest Nevraumont, a beacon for what modern learning can achieve through the power of artificial intelligence. Recent events around her presence at the 2026 State of the Union address make it clear: this isn't just a...

Continue Reading
Empowering Small Businesses: Mighty and Amazon Collaboration

Updated Category News Views 208

Strengthening the Bond Between Mighty and Amazon Business Recently, Mighty made headlines with the expansion of its Amazon Business In-Person Registration Program, aimed at providing practical onboarding and purchasing assistance to small businesses across North America. The program represents a significant development in how businesses can merge digital tools with...

Continue Reading
ProShares IQQQ ETF: A Strategic Choice for Income Investors

Updated Category News Views 226

Understanding the Current Market Landscape In the ever-evolving financial markets, significant changes can impact investment strategies. Recently, we witnessed noteworthy developments from the Federal Reserve, which adjusted its benchmark interest rate. This shift not only influences investor behavior but also reshapes the landscape for income-seeking individuals....

Continue Reading